ArticleEndocrinology2017
Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.
Article in Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 61 citations in OpenAlex.
- High‑fat diet exacerbates hepatic and adipose insulin signaling impairment and ovarian lesions in a rat model of letrozole‑induced polycystic ovary syndrome.Molecular medicine reports · 2026Article
- Testosterone Regulates Sex-Dependent Immune Responses and Androgen Receptor Expression DuringInternational journal of molecular sciences · 2026Article
- Systems genetics approaches model the heritable architecture of polyendocrine metabolic ovarian syndrome.The Journal of clinical investigation · 2026Article
- Therapeutic potential of harmine in polycystic ovarian syndrome: regulation of TNF-α/IL-6-mediated inflammation, Nrf2/keap-1 signaling, and ovarian steroidogenesis in Sprague-Dawley rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Toll-like receptor 4 knockout mice are protected against PMOS-like pathogenesis.Reproduction (Cambridge, England) · 2026Article
- Exploring the therapeutic potential of Lupeol isolated from Ochrosia elliptica Labill. leaves in polycystic ovarian syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- From Seed to Therapy: Sesamin and Phytosterols of Sesamum indicum in Polycystic Ovary Syndrome and Ovarian Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Curative potential of resveratrol and pterostilbene against epoxy resin-induced reproductive toxicity in female rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Toll-like Receptor 4 Contributes to PCOS-like Metabolic and Reproductive Pathogenesis.bioRxiv : the preprint server for biology · 2025Article
- Hippo signaling pathway in polycystic ovary syndrome.Frontiers in endocrinology · 2025Review
- Targeted inhibition of kisspeptin neurons reverses hyperandrogenemia and abnormal hyperactive LH secretion in a preclinical mouse model of polycystic ovary syndrome.Human reproduction (Oxford, England) · 2024Article
- Effects of the prenatal and postnatal nurturing environment on the phenotype and gut microbiota of mice with polycystic ovary syndrome induced by prenatal androgen exposure: a cross-fostering study.Frontiers in cell and developmental biology · 2024Article
- Development and evaluation of novel krill oil-based clomiphene microemulsion as a therapeutic strategy for PCOS treatment.Drug delivery and translational research · 2023Article
- Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome.Cells · 2023Review
- Mitoguardin2 Is Associated With Hyperandrogenism and Regulates Steroidogenesis in Human Ovarian Granulosa Cells.Journal of the Endocrine Society · 2023Article
- Efficiency of Chinese medicine Bushen Huatan formula for treatment of polycystic ovary syndrome in mice via regulating gut microbiota and PPARγ pathway.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023Article
- NGF and Its Role in Immunoendocrine Communication during Metabolic Syndrome.International journal of molecular sciences · 2023Review
- The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: A stereological study.International journal of reproductive biomedicine · 2022Article
- The Role of a High-Fat, High-Fructose Diet on Letrozole-Induced Polycystic Ovarian Syndrome in Prepubertal Mice.Nutrients · 2022Article
- Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats.Iranian journal of basic medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Women with polycystic ovary syndrome (PCOS) diagnosed with hyperandrogenism and ovulatory dysfunction have an increased risk of developing metabolic disorders, including type 2 diabetes and cardiovascular disease. We previously developed a model that uses letrozole to elevate endogenous testosterone levels in female mice. This model has hallmarks of PCOS, including hyperandrogenism, anovulation, and polycystic ovaries, as well as increased abdominal adiposity and glucose intolerance. In the current study, we further characterized the metabolic dysfunction that occurs after letrozole treatment to determine whether this model represents a PCOS-like metabolic phenotype. We focused on whether letrozole treatment results in altered pancreatic or liver function as well as insulin resistance. We also investigated whether hyperinsulinemia occurs secondary to weight gain and insulin resistance in this model or if it can occur independently. Our study demonstrated that letrozole-treated mice developed hyperinsulinemia after 1 week of treatment and without evidence of insulin resistance. After 2 weeks of letrozole treatment, mice became significantly heavier than placebo mice, demonstrating that weight gain was not required to develop hyperinsulinemia. After 5 weeks of letrozole treatment, mice exhibited blunted glucose-stimulated insulin secretion, insulin resistance, and impaired insulin-induced phosphorylation of AKT in skeletal muscle. Moreover, letrozole-treated mice exhibited dyslipidemia after 5 weeks of treatment but no evidence of hepatic disease. Our study demonstrated that the letrozole-induced PCOS mouse model exhibits multiple features of the metabolic dysregulation observed in obese, hyperandrogenic women with PCOS. This model will be useful for mechanistic studies investigating how hyperandrogenemia affects metabolism in females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.